

# Longitudinal monitoring for minimal residual disease

## Small, ultrasensitive NGS panels that deliver confident MRD detection via liquid biopsy throughout treatment

MRD monitoring for cancer can be time consuming, costly, and labor intensive. Many approaches to detecting MRD involve multiple testing strategies but are also reliant on significant disease progression to be effective like imaging or tumor biopsy.

Small, targeted NGS panels enable the ultrasensitive detection of MRD through the deep sequencing of mutations in cell-free DNA (cfDNA). They deliver significant variant redundancy for each liquid biopsy, increasing confidence that MRD can be detected throughout treatment and into remission.

## Design your own solution for MRD with Nonacus Cell3™ Target Custom Panels. Confidently call mutations down to 0.1% variant allele frequency from as little as 25 ng cfDNA

- Highly efficient target capture and unrivalled probe performance, even on panels <500 probes in size
- Online Panel Design Tool and rapid manufacture enables fast turnaround of highly targeted tumor specific NGS panels
- Streamlined liquid biopsy workflow from sample collection to analysis for longitudinal monitoring of MRD

### Download poster



Dr Mark Openshaw (University of Birmingham, UK) used Nonacus Cell3™ Target custom panels for investigating MRD in esophageal adenocarcinoma patients. This poster was presented at ESMO 2023.

For more information visit <https://nonacus.com/custom-panels-mrd/>